TIDMCRX

Cyprotex PLC

01 October 2013

Cyprotex PLC

("Cyprotex" or "the Company")

Cyprotex to expand its UK facility into BioHub at Alderley Park

1st October 2013; Cyprotex PLC (AIM:CRX), a specialist ADME-Tox Contract Research Organisation, announced today its plans for the expansion of its UK facility into BioHub, a new bioscience centre at AstraZeneca's Alderley Park research campus near Manchester, England.

BioHub will provide Cyprotex with additional capacity for laboratories and office space. The new laboratories include fully equipped cell culture facilities and radiochemical handling capabilities enabling Cyprotex to continue its growth strategy into new areas supporting preclinical drug discovery projects.

This expansion follows highly encouraging growth figures for the business in the first six months of the year, with a revenue increase of 22.3% in H1 compared to the same period in 2012 and a record half yearly operating profit of GBP317,000. Performance remains strong across all of our geographical markets and our main service operations of high throughput ADME, customised ADME and toxicology.

Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments: "As we continue to see significant growth in our business, it has been necessary to expand our facilities to meet the increased demand. We are therefore delighted to announce the signing of a lease for new cutting-edge facilities at BioHub in Alderley Park. The location of the facility is ideal for transport links, both by air and road, which is important as Cyprotex expands its international footprint."

For further information:

 
 Cyprotex PLC                                 Tel: +44 (0) 1625 505 
                                               100 
 Dr Anthony Baxter, Chief Executive Officer   ir@cyprotex.com 
  John Dootson, Chief Financial Officer        www.cyprotex.com 
  Mark Warburton, Chief Operating Officer 
  and Legal Counsel 
 
 N+1 Singer (Nomad and broker to Cyprotex)    Tel: +44 (0)20 7496 
                                               3000 
 Shaun Dobson                                 shaun.dobson@n1singer.com 
  Jenny Wyllie                                 jenny.wyllie@n1singer.com 
                                               www.n1singer.com 
 
 FTI Consulting                               Tel: +44 (0) 20 7831 
                                               3113 
 Simon Conway                                 cyprotex@fticonsulting.com 
  Mo Noonan                                    www.fticonsulting.com

Notes to Editors

About Cyprotex PLC

Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, MA in the US and is listed on the AIM market of the London Stock Exchange (CRX). The Company was established in 1999 and works with more than 700 partners ranging from small biotechs to large pharma companies. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The Company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services and predictive modelling using PBPK and QSAR techniques. For more information, see www.cyprotex.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRABLGDCRSXBGXG

Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Cyprotex Charts.
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Cyprotex Charts.